Quick summary
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) bioregulator by Khavinson targeting bronchial and pulmonary tissue. It modulates lung epithelial gene expression, reduces pulmonary inflammation by inhibiting TNF-alpha, and regulates respiratory antioxidant defenses.
Overview
Chonluten is a synthetic tripeptide bioregulator (Glu-Asp-Gly, EDG) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, targeting the bronchial and pulmonary tissue. It is studied for its ability to modulate lung epithelial gene expression, reduce pulmonary inflammation, and regulate antioxidant defenses in the respiratory system.
Mechanism of action
Chonluten penetrates bronchial epithelial cells and translocates to the nucleus, where it directly interacts with DNA in a tissue-specific manner to modulate gene transcription patterns associated with inflammation and oxidative stress. In preclinical studies, Chonluten inhibited TNF-α production by monocytes exposed to bacterial lipopolysaccharide (LPS), demonstrating anti-inflammatory activity at the cytokine level. It modulates the expression of genes involved in antioxidant activity, mucin regulation, and bronchial epithelial barrier integrity. As with other Khavinson bioregulators, its specificity arises from the peptide's preferential interaction with promoter sequences in lung tissue cells via minor groove DNA binding, activating regenerative transcriptional programs in aged or damaged pulmonary tissue.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| pulmonary/respiratory research | subcutaneous | 0.1–0.5 mg | daily for 10–20 days | Standard Khavinson cytogen protocol: 10-day injection cycles, 2–4 times per year. |
| oral research use | oral | 1–2 mg | daily | Sublingual route is also used in Russian clinical practice for bioregulator peptides. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Research from Khavinson's group shows Chonluten's capacity to restore bronchial epithelial cell function in aged tissue models, reduce inflammatory cytokine production in stimulated human immune cell assays, and modulate antioxidant gene expression in lung tissue. Animal studies suggest protective effects in oxidative pulmonary stress models. Human research is limited to Russian clinical series. No published RCTs in the Western peer-reviewed literature exist. Preclinical findings are promising for age-related pulmonary decline but require independent replication.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Chonluten for synergistic effects.
Legal status
Not FDA-approved. Developed and studied in Russia; commercially available in Russia as a bronchopulmonary bioregulator supplement. Available in Western markets as a research chemical only.
Sourcing & access
Research compound
Chonluten is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Chonluten is a synthetic tripeptide (EDG) from the Khavinson bioregulator family, targeting bronchial and pulmonary tissue. It is studied for its ability to modulate lung epithelial gene expression, reduce pulmonary inflammation, and regulate respiratory antioxidant defenses.
Chonluten penetrates bronchial epithelial cells and interacts with DNA promoter sequences via minor groove binding, modulating genes involved in antioxidant activity, mucin regulation, and bronchial epithelial barrier integrity. It inhibits TNF-alpha production by monocytes exposed to bacterial lipopolysaccharide.
Reported side effects are limited to mild injection site irritation. The long-term safety profile is unknown. Research consists primarily of Russian preclinical and clinical series without Western peer-reviewed RCTs. It is not FDA-approved.
Standard Khavinson protocols use 0.1 to 0.5 mg subcutaneously daily for 10-day cycles, repeated 2 to 4 times per year. Oral or sublingual dosing of 1-2 mg daily is also used in Russian clinical practice.